Celularity Inc

Celularity Inc. (ticker: GXGX) is a clinical-stage biotechnology company focused on placental-derived cell therapies and allogeneic cellular medicine that entered public markets through a SPAC merger in the healthcare and life sciences sector. The blank-check vehicle, GX Acquisition Corp., was sponsored by GX Sponsor LLC and completed its IPO in 2020. Celularity currently operates as a publicly traded post-merger entity subject to ongoing SEC reporting requirements. On December 23, 2025, the company filed an 8-K current report with the SEC under accession number 0001493152-25-029033, disclosing a material corporate event. Sign up on SpacDesk for the full filing history, deal analytics, and real-time alerts across the SPAC universe.